Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interleukin-7 and Chemokine (C-C Motif) -Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma

NCT03929107 is registered in ClinicalTrials.gov with Wenbin Qian as lead sponsor.

NCT NCT03929107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03929107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interleukin-7 and Chemokine (C-C Motif) -Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma
Lead sponsor
Wenbin Qian
Phase
Phase 2
Overall status
Unknown status
Start date
March 28, 2019
Completion date
April 30, 2022
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b cell lymphoma